Breaking News, Collaborations & Alliances

Ideaya Biosciennces Enters Clinical Trial Collaboration & Supply Agreement with Merck

Will evaluate IDE161 in combination with KEYTRUDA in patients with endometrial cancer.

Author Image

By: Charlie Sternberg

Associate Editor

Ideaya Biosciences Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, has entered into a clinical trial collaboration and supply agreement with Merck to evaluate IDE161, the company’s investigational small molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with microsatellite instability-, or MSI-, high and microsatellite stabl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters